Sonographic examination with microbubble contrast agents can reliably characterize focal liver lesions, confirm or exclude hepatocellular carcinomas, and remove the need for more invasive, costly imaging, according to studies presented Monday.
Sonographic examination with microbubble contrast agents can reliably characterize focal liver lesions, confirm or exclude hepatocellular carcinomas, and remove the need for more invasive, costly imaging, according to studies presented Monday.
Canadian researchers used contrast-enhanced ultrasound to evaluate 80 patients who presented during a nine-month period with 106 hepatic nodules that had a high likelihood of becoming malignant. The researchers characterized lesions during dynamic and portal vein phase scanning based on the lesions' enhancement patterns. They found that contrast sonography could characterize lesions early and obviate further scanning with CT or MR.
Contrast ultrasound confirmed 46 lesions as HCC, 31 as dysplastic/regenerative nodules, 16 as hemangiomas, eight as pseudomasses, and five as indeterminate nodules. Twenty-one out of 37 nodules detected at initial scanning were benign and were subjected to close surveillance with ultrasound only. None of these lesions evolved into HCC after the nine-month follow-up. Fifteen nodules were diagnosed as HCCs and one as a pseudomass.
Of 69 lesions with an indeterminate diagnosis at initial CT/MR scanning, contrast ultrasound identified 30 HCCs, 19 dysplastic/regenerative nodules, seven hemangiomas, and eight pseudomasses.
In a similar study, Italian researchers enrolled 191 consecutive patients with chronic diffuse liver disease due to chronic hepatitis B or C and cirrhosis. Using microbubble contrast sonography, the researchers accurately differentiated HCCs from other focal liver lesions.
As in the previous study, the investigators used the lesions' enhancement patterns at different phases to calculate positive predictive values. Two independent observers reviewed the studies. HCCs showed 40 diffuse homogeneous, 56 heterogeneous, 10 dotted, and five absent enhancement patterns at arterial phase. HCC also appeared as 71 hypoechoic lesions and 40 isoechoic lesions at late phase.
The investigators obtained the highest positive predictive value for HCCs by combining diffuse heterogeneous enhancement at arterial phase with hypoechoic appearance at late phase, with a PPV of 94% and overall accuracy in HCC characterization of 92%.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Intestinal Ultrasound Provide an Alternative for Evaluating Creeping Fat with Crohn’s Disease?
September 25th 2024Intestinal ultrasound demonstrated an 88.2 percent agreement with computed tomography enterography in characterizing creeping fat in patients with Crohn’s disease, according to new research.
FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
September 23rd 2024The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.